The mission and vision of the ACRF Image X Institute is to create, share and apply scientific knowledge to improve human health. We focus on developing and improving anatomic and physiologic cancer imaging methods and integrating these innovations into adaptive medical therapeutic systems, particularly radiation therapy.
A critical step in applying our technology is the translation of our technology through clinical trials. We are involved in clinical trials where Prof Keall, ACRF Image X Institute members and the University of Sydney may hold patents and other intellectual property and may benefit financially from the results of the trials.
We also partner in clinical trials with external companies, including start-ups from our laboratory, in trials where we may benefit financially from the results of the trials. ACRF Image X Institute members work with the University to identify and best manage these conflicts.
Professor Paul Keall
Leo Cancer Care has been assigned a linear accelerator patent.
Opus Medical has licensed an audiovisual biofeedback patent.
Leo Cancer Care has licensed kV image-guided radiotherapy methods.
Standard Imaging has licensed a motion platform design from Virginia Commonwealth University.
Varian has licensed kV, MV and respiratory monitoring-based image-guided radiotherapy methods from Stanford University.
Leo Cancer Care has licensed a kV image-guided radiotherapy method from Stanford University.
IBA, Co-Investigator (Principal Investigator Brad Oborn) for MRI-guided particle therapy research.
Philips (Principal Investigator), for a loan of a treatment planning system for research.
Varian, Co-Investigator (Principal Investigator Jeremy Booth) for equipment and support for MLC tracking and KIM.
Siemens (Principal Investigator with Ricky O’Brien) on four-dimensional imaging research.
Varian, Principal Investigator, for MRI treatment planning research.
Partner (100% stake) in Cancer Research Innovations, a business which owns intellectual property related to image guided radiotherapy methods and systems.
Founder, 20% shareholder and director of Opus Medical Pty Ltd, a company advancing the Breathe Well audiovisual biofeedback device.
Founder of Leo Cancer Care, a company developing a real-time image-guided cancer radiotherapy system.
Founder, 100% shareholder and director of SeeTreat Pty Ltd, a company that is advancing MRI-guided cancer radiotherapy.
Associate Professor Ricky O’Brien
Siemens (Principal Investigator with Paul Keall) on four-dimensional imaging research.
Founder, 5% shareholder and hardware and software developer for Opus Medical Pty Ltd, a company advancing the Breathe Well audiovisual biofeedback device.
Founder, 5% shareholder, part-time employee and hardware and software developer for Opus Medical Pty Ltd, a company advancing the Breathe Well audiovisual biofeedback device.